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OBJECTIVES: To assess the cost-effectiveness of erlotinib versus
docetaxel and pemetrexed for second-line treatment of advanced
NSCLC in Taiwan, from a payer’s (Bureau of National Health
Insurance [BNHI]) perspective. METHODS: A health state-
transition Markov model was developed to evaluate incremental
cost-effectiveness in terms of cost per quality-adjusted life year
(QALY). Clinical outcomes were derived from the pivotal phase
III studies of erlotinib (BR.21), docetaxel (TAX317) and pemetr-
exed (JMEI). Progression-free and post-progression survival were
modeled using the actuarial method of Kaplan-Meier analysis,
with a 2-year time horizon and a cycle length of 1 month. Direct
medical costs associated with drug acquisition and drug admin-
istration were based on Taiwan’s National Health Insurance fee
schedule (2007). Costs for medical resource utilisation and
adverse event management were estimated from an expert panel
survey including six oncologists. Health-related utility scores
were collected from a utility study conducted among 154 people
in the UK by applying the EQ-5D York tariff and the EQ-5D
visual analogue scales. Costs and health outcomes were
discounted at an annual rate of 3.5%. One-way deterministic
sensitivity analyses were performed on key model parameters by
varying the input values by 10%. RESULTS: Erlotinib was
dominant versus both docetaxel and pemetrexed, with base case
incremental cost-effectiveness ratios (ICERs) of –NTD $188,205
(-€4,255) and –NTD $3,309,629 (-€74,828) per QALY, respec-
tively. In sensitivity analyses, the ICER of erlotinib versus
docetaxel ranged from dominant to NTD $228,180 (€5,159)
per QALY. Erlotinib remained dominant versus pemetrexed in
sensitivity analyses. The results obtained were most sensitive to
changes in drug acquisition costs. CONCLUSION: From the
perspective of the Taiwan BNHI, this pharmacoeconomic analy-
sis demonstrates that the use of erlotinib as second-line treatment
of advanced NSCLC would not only save direct medical costs but
also improve health outcomes compared with docetaxel and
pemetrexed.
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OBJECTIVES: To estimate cost-effectiveness of dasatinib vs.
imatinib in chronic-phase CML after failure of ﬁrst-line imatinib
from the perspective of the Austrian Social Healthcare Insurance
System. METHODS: Long-term cost-effectiveness of dasatinib
(2 ¥ 70 mg/day) vs. imatinib (800 mg/day) was modeled with a
Markov model using initial best response from a randomized
clinical trial in chronic-phase CML patients resistant to 400–
600 mg imatinib. Model simulation runs in monthly cycles until
all patients have died. Disease progression depends on initial best
response and current health-state, and was simulated according
to literature based monthly transition-probabilities. Occurrence
of serious adverse events (SAEs) was drawn from trial observa-
tions. Utilities were obtained from a CML utility study using
EQ-5D, life expectancy from national statistics. Health care uti-
lization and costs were derived from panels of clinical and
ﬁnance experts, databases of 24 hospitals across Austria and
Austrian drug price list. Both costs and effects were discounted
annually at 5%. Sensitivity analyses on efﬁcacy, costs and utilities
were performed. RESULTS: Treating patients with dasatinib is a
dominant treatment strategy compared to treatment with high
dose of imatinib over lifetime time. Over lifetime, dasatinib is
associated with a gain of 0.57 QALY (95% CI: -0.25 to 1.42)
and considerable cost savings of €15,213 (95% CI: -€40,220 to
€71,522). Dasatinib is also a dominant treatment strategy at a
1-year time horizon. While the utility component is driven by
efﬁcacy results, the cost component is driven by drug use and
outpatient visits rather than management of SAEs and imaging/
testing services. Results were robust to sensitivity analyses.
CONCLUSION: Dasatinib is associated with increased effective-
ness and cost savings to the Austrian health care system, and can
be considered an improvement in treatment of chronic-phase
CML patients after failure of ﬁrst-line imatinib.
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OBJECTIVES: Novel therapies for cancer have been developed
that interfere with speciﬁc molecules involved in tumor growth.
These therapies are generally more expensive than traditional
therapies and have drawn scrutiny from health care policymak-
ers. Cost-effectiveness analysis (CEA) is an accepted tool to pri-
oritize health care interventions. We conducted a review of the
CEA literature on these targeted oncologics to determine if their
premium prices are justiﬁed. METHODS: A systematic review of
the cost-effectiveness literature published between January 1997
and May 2007 was conducted for the following agents: alemtu-
zumab, bevacizumab, bortezomib, cetuximab, erlotinib, geﬁ-
tinib, gemtuzumab, imatinib, rituximab, sorafenib, sunitinib,
tositumomab, and trastuzumab. Exclusion criteria included:
publications not available in English, letters to the editor,
opinion-based articles, review articles, abstracts only, health
technology assessments, and studies of diseases other than
cancer. Relevant data from the included articles were extracted to
summary tables. RESULTS: Eighteen articles met the inclusion
and exclusion criteria. Six articles evaluated trastuzumab for
breast cancer, 5 examined imatinib for chronic myelogenous
leukemia, and 4 studied rituximab for diffuse large B-cell lym-
phoma. The remaining 3 articles examined imatinib, bortezomib,
and cetuximab therapy for gastrointestinal stromal tumors, mul-
tiple myeloma, and metastatic colorectal cancer respectively. Tar-
geted therapeutics exceeded the threshold of 50,000 dollars/
euros or 30,000 pounds in only 5 out of 22 scenarios
(cetuximab + irinotecan vs. best supportive care, imatinib vs.
hydroxycarbamide, imatinib vs. hydroxyurea, imatinib vs. com-
bination therapy (blast crisis), trastuzumab vs. standard chemo-
therapy). CONCLUSION: Less than half of the targeted
oncologics studied have been evaluated by the standard tech-
nique of CEA. The majority of the CEAs reviewed adhered to
Abstracts A325
